Abstracts Archive - Page 331 of 1683 - ATC Abstracts

2020 American Transplant Congress
Treprostinil is Safe and Potentially Useful in Preventing Ischemia and Reperfusion Injury in Adult Orthotopic Liver Transplant Recipients
R. Venkataramanan¹, I. H. Shaik², V. C. Pillai³, O. A. Almazroo⁴, M. K. Miah⁵, R. Xu², S. Dharmayan², A. Al-Khafaji², S. Ganesh², M. Molinari², A. Tevar², C. Hughes², A. Humar²
¹School Of Pharmacy, University of Pittsburgh, Pittsburgh, PA, ²University of Pittsburgh, Pittsburgh, PA, ³US Food and Drug Administration,, Silver Spring, MD, ⁴Saudi FDA, Riyadh, Saudi Arabia, ⁵Astra Zeneca, Boston, MA
*Purpose: Ischemia and reperfusion injury (IRI) is one of the unavoidable complications in orthotopic liver transplantion. Hepatic ischemic injury begins during the preservation of the…
2020 American Transplant Congress
Molecular Diagnosis of Rejection in Liver Transplant Biopsies: The INTERLIVER Study
K. S. Madill-Thomsen¹, P. F. Halloran², .. The INTERLIVER Study Group³
¹Alberta Transplant Applied Genomics Centre, Edmonton, AB, Canada, ²University of Alberta, Edmonton, AB, Canada, ³., ., AB, Canada
*Purpose: Diagnosing rejection in liver transplant biopsies is challenging given the limitations of histology e.g. low kappa values among pathologists. A Molecular Microscope® Diagnostic system…
2020 American Transplant Congress
Incidence of Rejection One Year after Liver Transplantation Associated with Early versus Late Steroid Withdrawal
S. Yun, L. Miko, J. Ahmad
The Mount Sinai Hospital, New York, NY
*Purpose: The adverse effects associated with steroid use make earlier steroid withdrawal desirable, but the optimal time for withdrawal after liver transplantation (LT) is not…
2020 American Transplant Congress
Impact of Donor Race on Tacrolimus Dose Requirement for Liver Transplant Recipients
N. Nesselhauf¹, S. January¹, J. Hagopian¹, K. Progar¹, A. Khan²
¹Pharmacy, Barnes-Jewish Hospital, St. Louis, MO, ²Surgery, Washington University School of Medicine, St. Louis, MO
*Purpose: It is well described that there is interpatient variability in tacrolimus dose requirements among transplant recipients. CYP3A5 plays a role in this variability. Black…
2020 American Transplant Congress
Stanford Integrated Psychosocial Assessment for Transplant Predicts Immunosuppression Non-Adherence after Liver Transplantation
S. Deutsch-Link¹, E. Weinberg², M. McDougal³, L. Jones⁴, T. Bitterman², M. Serper²
¹Medicine, University of Pennsylvania, Philadelphia, PA, ²Gastroenterology & Hepatology, University of Pennsylvania, Philadelphia, PA, ³Drexel University, Philadelphia, PA, ⁴PCOM, Philadelphia, PA
*Purpose: Patients with end-stage liver disease presenting for liver transplant (LT) evaluation have a high burden of psychosocial comorbidities. The Stanford Integrated Psychosocial Assessment for…
2020 American Transplant Congress
Impact of the Baseline Anti-A/B IgG Titer on the Clinical Outcome in ABO-Incompatible Liver Transplantation
J. Lee¹, E. Kim¹, S. Yang¹, D. Kim², M. Ju³, J. Lee¹, M. Kim¹, S. Kim¹, D. Joo¹
¹Department of Transplantation Surgery, Severance Hospital, Seoul, Korea, Republic of, ²Department of Surgery, Yonsei University Wonju College of Medicine, Wonju, Korea, Republic of, ³Department of Surgery, Gangam Severance Hospital, Seoul, Korea, Republic of
*Purpose: The use of ABO incompatible (ABOi) living donors is an attractive solution for expanding the liver donor pool. We investigated the impact of the…
2020 American Transplant Congress
Treatment of De Novo Renal Transplant Recipients with Calcineurin Inhibitor (CNI)-Free, Belatacept+Everolimus-Based Immunosuppression
V. R. Peddi¹, B. Marder², L. Gaite³, J. Oberholzer⁴, R. Goldberg⁵, T. Pearson⁶, H. Yang⁷, L. Allamassey⁸, S. Gao⁸, M. Polinsky⁸, R. N. Formica⁹
¹California Pacific Medical Center, San Francisco, CA, ²Colorado Kidney Care, Denver, CO, ³Hospital Marqués de Valdecilla, Cantabria, Spain, ⁴UVA Health, Charlottesville, VA, ⁵Saint Barnabas Medical Center, Livingston, NJ, ⁶Emory University School of Medicine, Atlanta, GA, ⁷UPMC Pinnacle, Harrisburg, PA, ⁸Bristol-Myers Squibb, Princeton, NJ, ⁹Yale University School of Medicine, New Haven, CT
*Purpose: Compared with CNI-based immunosuppression, kidney transplant recipients receiving belatacept-based treatment present with a favorable metabolic profile, reduced chronic allograft nephropathy, and improved renal function,…
2020 American Transplant Congress
Evaluation of Leukopenia and Neutropenia Incidence, Treatment, and Clinical Response in Kidney and Liver Transplant Recipients
H. Kutzler, T. Webb, R. Cecere, D. O'Sullivan, P. Sheiner
Hartford Hospital, Hartford, CT
*Purpose: The purpose is to evaluate incidence, recurrence, therapy modifications, and complications of leukopenia and neutropenia (LN) in kidney (KTR) and liver transplant (LTR) recipients.*Methods:…
2020 American Transplant Congress
Use of Cell Saver Leads to Lower Consumption of Blood Products During Liver Transplantation
R. Danc
Anesthesiology, Ikem, Prague, Czech Republic
*Purpose: Liver transplantation is often accompanied by significant blood loss and consequently a large consumption of blood products. In recent years, there has been a…
2020 American Transplant Congress
Efficacy & Safety of Once Daily Tacrolimus Compared to Twice Daily Tacrolimus after Liver Transplantation
K. Bzeizi, A. Albenmousa, M. Shawkat, W. Alhamoudi, S. Alabad, R. Troisi, D. Broering
KFSHRC, Riyadh, Saudi Arabia
*Purpose: To compare the efficacy and safety of once daily prolonged release tacrolimus compared to twice daily tacrolimus in liver transplantation patients*Methods: Medline, EMBASE, CENTRAL…